If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...
Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...
WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...
The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...
BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...
European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen ...
The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduction, better weight loss ...
AstraZeneca PLC AZN announced that the European Commission has granted approval to Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of its GLP-1 receptor agonist ...
Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, BYDUREON BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results